Clinical trial Recruiting at 1 site Interventional Ages 19 to 80

Personalized anti-platelet therapy for high-risk patients after stent placement

Official title: A Randomized Comparison of TAILOReD Anti-Platelet Therapy According to Platelet Reactivity Versus Uniform Clopidogrel Monotherapy Beyond 12 Months After Drug-eluting Stent Implantation in High-risk Patients: TAILOR-DAPT

Run by Yonsei University · NCT05936606 · Data updated 2026-11-12

This study is testing if a personalized anti-platelet treatment can help high-risk patients who have had a stent placed feel better than just taking standard medication alone.

Quick facts

Study typeInterventional
Ages19 Years to 80 Years
SexAll
Enrollment3434 (estimated)
SponsorYonsei University
Academic / other
Locations1 site (Seoul)
StatusRecruiting
StartedAugust 16, 2023
Main results expectedMay 2027
Study endsMay 2029
Registry record updatedAugust 30, 2023
Trial IDNCT05936606 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients over 50 years old who have undergone DES implantation and exhibit high-risk characteristics for ischemic events.

Probably not a fit

Patients over 80 years old or those who are pregnant will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a tailored anti-platelet therapy strategy for high-risk patients who have undergone drug-eluting stent (DES) placement. Participants will be randomly assigned to either continue standard clopidogrel monotherapy or receive personalized treatment based on their platelet reactivity. The intervention aims to optimize antiplatelet therapy beyond 12 months post-stenting, particularly for those with high platelet reactivity. The study will monitor outcomes over a period of up to 24 months.

Why it matters

Potential benefit: If successful, this approach could significantly reduce the risk of ischemic events and bleeding complications in high-risk patients after stent placement.

How similar studies have gone: Other studies have shown promise in personalized antiplatelet therapy, but this specific approach in high-risk DES patients is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients \> 18 years old
2. Patients who previously underwent percutaneous coronary intervention with drug-eluting stent implantation 12 months (± 3 months) ago.
3. At least one high risk characteristics of ischemic events

High risk patients

1. Acute coronary syndrome
2. Previous history of cerebrovascular accidents
3. Previous history of peripheral artery intervention
4. Heart failure
5. Diabetes mellitus requiring medication
6. Chronic kidney disease (regardless of requirement of renal replacement therapy)

High risk lesions

1. Left main disease
2. Multivessel disease, 2- or 3- vessels
3. Bifurcation lesions requiring 2 or more stents
4. Chronic total occlusion
5. In-stent restenosis
6. Graft lesions
7. Diffuse long lesion requiring stent(s) with total stent length ≥28 mm
8. Lesion at small sized vessel requiring stent(s) with stent diameter ≤2.5 mm
9. Calcified lesions requiring atherectomy

Exclusion Criteria:

1. Patients \> 80 years old
2. Pregnant women or women with potential childbearing
3. Life expectancy \< 1 year
4. Refusal or inability to understand of informed consent
5. Patients eligible to long-term anticoagulation therapy
6. Patients with major bleeding events in previous 3 months before randomization

Where it's running

  • Severance Hospital
    Seoul, South Korea
    Recruiting

Study contacts

  • Principal investigator: Byeong-Keuk Kim — Severance Cardiovascular Hospital
  • Study coordinator: Byeong-Keuk Kim
  • Email: kimbk@yuhs.ac
  • Phone: 02-2228-8465

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.